VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
GALT
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
GALTGalectin Therapeutics Inc.
$3.05$201M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. GALT
  4. Financial Ratios

Galectin Therapeutics Inc. (GALT) Financial Ratios

Latest Ratios: P/E Ratio -11.7x · EV/EBITDA N/A · ROE N/A. (2000–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

GALT Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Market Cap$199M$266M$80M$100M$67M$121M$128M$149M$135M$119M$29M
Enterprise Value$315M$382M$172M$146M$88M$111M$101M$102M$127M$116M$13M
P/E Ratio →-11.67——————————
P/S Ratio———————————
P/B Ratio—————46.315.283.2819.6099.452.38
P/FCF———————————
P/OCF———————————

P/E links to full P/E history page with 30-year chart

GALT EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
EV / Revenue———————————
EV / EBITDA———————————
EV / EBIT———————————
EV / FCF———————————

GALT Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Gross Margin———————————
Operating Margin———————————
Net Profit Margin———————————

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
ROE—————-227.7%-67.2%-50.7%-343.6%-245.8%-115.7%
ROA-166.6%-166.6%-205.9%-166.0%-122.9%-85.5%-60.1%-46.3%-211.1%-162.7%-101.6%
ROIC———————————
ROCE-174.6%-174.6%—-366.1%-186.8%-105.9%-67.1%-51.1%-336.2%-246.0%-115.9%

GALT Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Debt / Equity—————11.110.000.00———
Debt / EBITDA———————————
Net Debt / Equity—————-4.05-1.12-1.04-1.20-2.56-1.28
Net Debt / EBITDA———————————
Debt / FCF———————————
Interest Coverage-3.21-3.21-7.49-13.71-36.54-61.43-268.71-151.80-40.37-1352.92—

GALT Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Current Ratio2.422.420.491.771.584.635.4617.104.191.294.18
Quick Ratio2.422.420.491.771.584.635.4617.104.191.294.18
Cash Ratio2.212.210.431.641.434.395.0316.843.921.034.06
Asset Turnover———————————
Inventory Turnover———————————
Days Sales Outstanding———————————

GALT Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Dividend Yield——0.1%——0.1%0.1%0.3%0.7%1.0%2.6%
Payout Ratio———————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Earnings Yield———————————
FCF Yield———————————
Buyback Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Total Shareholder Yield0.0%0.0%0.1%0.0%0.0%0.1%0.1%0.3%0.7%1.0%2.6%
Shares Outstanding—$64M$62M$60M$59M$59M$57M$52M$39M$36M$29M

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Debt overhang versus vanishing liquidity

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q2)

Current Ratio Collapse Flags Immediate Strain

GALT's current ratio plunged from 2.15 in 2026Q1 to 0.10 in 2026Q2, per its quarterly balance sheets, implying near-term obligations exceed liquid assets roughly tenfold and marking the weakest liquidity reading in the ten-quarter series.

The 0.10 current and quick ratios in 2026Q2 are identical, which indicates the entire current asset base is effectively cash-like — consistent with the $13.3M cash position against $151.7M in total liabilities reported elsewhere in the balance sheet. The swing from 2.15 to 0.10 within a single quarter suggests either a large current-maturity reclassification of the $137.7M debt load or an abrupt settlement of current obligations; either way, the buffer against a missed payment or covenant event appears negligible, and investors should monitor the maturity schedule disclosed in the notes for near-term refinancing dependence. Under stress, this profile implies the company would likely need an immediate financing event to meet obligations maturing within twelve months, though the exact timing cannot be confirmed from ratio data alone.

Coverage Improving From a Meaningless Base

Interest coverage improved from -9.92 in 2024Q1 to -0.41 in 2026Q2, according to Galectin's reported results, a trend driven entirely by the R&D-driven contraction in operating losses rather than any expansion in earnings available to service debt.

The arithmetic improvement in coverage mirrors the 68% reduction in quarterly operating losses noted in prior income statement analysis — when losses shrink, the denominator shrinks toward zero, mechanically lifting a negative coverage ratio without adding any real debt-service capacity. With $137.7M in total debt against $14.8M in total assets and a negative $136.9M equity position, the relevant question is not coverage but repayment source: no operating cash flow exists to amortize principal, so the structure appears dependent on refinancing, conversion, or negotiated extension. The D/E ratio is unavailable in this dataset, but the 9.3x debt-to-asset figure from the balance sheet analysis frames the true leverage far more meaningfully than any book-based ratio could.

Zero Revenue Leaves Margins Undefined

GALT's ROA has run between -28.6% and -71.3% over ten quarters through 2026Q2, per reported financial statements, reflecting pure cash burn against a shrinking asset base rather than operating underperformance, since gross, operating, and net margins remain undefined absent any revenue.

The ROA volatility — from -71.3% in 2025Q1 to -28.6% in 2026Q1 before reverting to -59.9% in 2026Q2 — tracks the sequential R&D spending cuts documented in the income statement analysis rather than any shift in earning power; the -59.9% reading likely reflects the $9.1M net loss in 2026Q2, which exceeded the $4.0M operating loss by $5.1M of below-the-line items. Because no margin metric is computable, profitability here is effectively a function of burn rate alone, and the apparent improvement in losses is a cost-retrenchment story, not a margin-expansion story. Analysts should treat the net-loss-to-operating-loss gap as the key quality-of-earnings flag, since it suggests non-operating volatility that could recur regardless of the trimmed R&D budget.

Asset Turnover Unavailable, Working Capital Signals Mixed

Asset turnover, DSO, DIO, DPO, and the cash conversion cycle are all unavailable for GALT across the ten-quarter window through 2026Q2, per its reported ratio disclosures, reflecting a business with no inventory, receivables, or payables scale sufficient to generate meaningful turnover metrics.

Working capital nevertheless contributed $6.6M of cumulative cash over the period per the cash flow statements, with 2026Q2 adding $2.5M — a favorable swing that partially offsets the operating burn but appears too small relative to the $151.7M liability stack to change the runway math materially. With zero capex across all ten quarters, the traditional cash conversion cycle framework offers no analytical traction; the relevant efficiency question for GALT is burn-per-quarter against undisclosed cash balances, not days-sales-outstanding dynamics. Given the 0.10 current ratio in 2026Q2, any working capital contribution in future quarters would more likely reflect deferral of payables than genuine operational efficiency, warranting scrutiny of accrual movements in upcoming filings.

Peer Set Highlights Structural Distinction

Against peers like MDGL (-56.6% ROE) and CRNX (-44.2% ROE), GALT's ROE is unavailable per reported data, yet its -59.6% ROA in 2026Q2 and zero-revenue profile place it at the extreme end of a pre-commercial cohort already pricing pipeline optionality.

Where MDGL and CRNX at least carry commercial-stage or late-stage pipelines supporting $10.2B and $9.0B valuations, GALT's reported figures show no revenue in ten quarters alongside a $137.7M debt load that peers of its scale do not carry — CRNX's 0.05 D/E and ELVN's 0.00 D/E underscore how unusual this capital structure is for a pre-revenue biotech. Halozyme's 50.2x P/E and 19.1x EV/EBITDA demonstrate what commercial success looks like in the sector, but those multiples are inapplicable to GALT given its undefined EV/EBITDA and P/S. The structural question for GALT versus this group is not whether margins lag, but whether the debt overhang — unique among the peer set shown — has already impaired equity recovery potential relative to unencumbered peers.

Debt-to-Equity Is the Misapplied Ratio Here

D/E, unavailable for GALT per reported disclosures, is the ratio most commonly misapplied to distressed biotechs, and its book-based construction would understate GALT's true economic leverage given the negative $136.9M equity base rendering any D/E figure either meaningless or infinite.

With shareholders' equity already negative $136.9M against $137.7M of debt and $446.8M in accumulated deficits, conventional leverage ratios collapse into arithmetic noise, while the 9.3x debt-to-asset ratio and the 0.10 current ratio from 2026Q2 convey the solvency picture far more honestly. The more useful diagnostic is the interplay between the quarterly burn (narrowed to roughly $2.4M per the FCF analysis) and the undisclosed cash balance versus the debt maturity profile — a relationship no single standard ratio captures. Additionally, if the convertible notes carry embedded derivative liabilities or anti-dilution features not itemized in summary data, as the prior balance sheet analysis flags, reported debt itself may understate the claim on future equity value, meaning investors should anchor on convertible terms disclosed in the notes rather than on any headline leverage multiple.

Download Financial Ratios Data

Includes 30+ ratios · 26 years · Updated daily

Consensus & Technical Research Suite
Open GALT Terminal

GALT Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

GALT — Frequently Asked Questions

Quick answers to the most common questions about buying GALT stock.

What is Galectin Therapeutics Inc.'s P/E ratio?

Galectin Therapeutics Inc.'s current P/E ratio is -11.7x. This places it at the 50th percentile of its historical range.

Is GALT stock overvalued?

Based on historical data, Galectin Therapeutics Inc. is trading at a P/E of -11.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.